Impact of HIV-infection on Clinical Characteristics and Outcomes on Stroke in Uganda

Sponsor
Mbarara University of Science and Technology (Other)
Overall Status
Completed
CT.gov ID
NCT03072212
Collaborator
Massachusetts General Hospital (Other)
200
1
46
4.4

Study Details

Study Description

Brief Summary

The investigators will recruit participants from three tertiary care hospitals in Uganda into an observational cohort study of people living with HIV/AIDS (PLWHA) and HIV-uninfected persons matched for gender and residency, presenting with CT-confirmed stroke. We will collect socio demographic, clinical, laboratory, radiologic, cardiac, and clinical neurologic disease measures to investigate the effect of HIV-infection on 1) clinical and radiologic presentation, 2) risk factor profiles; and 3) stroke outcomes (death or disability).

Condition or Disease Intervention/Treatment Phase
  • Other: Observational study

Detailed Description

The investigators will enroll 100 HIV-infected adults presenting to the emergency department with acute or sub-acute stroke (within 14 days of onset) confirmed by computed tomography (CT) scan at Mbarara Regional Referral, Mulago National Referral, and Nsambya Hospitals in Uganda. We will also enroll 100 HIV-uninfected controls, also presenting with acute or sub-acute stroke, matched by gender and county/district of residence. Participants will be followed for up to one year after enrollment. We plan to complete the following research aims:

Aim 1: To identify the impact of HIV-infection on outcomes after acute or sub-acute stroke in Uganda. Our primary outcome will be poor stroke outcome defined as mortality or poor functional status (modified Rankin Scale [mRS] > 2). The investigators will assess for mortality and functional status at one, three, six, and 12 months after presentation. We will estimate the relative risk of poor outcome by HIV serostatus in both unadjusted models and models adjusted for traditional stroke risk factors. We hypothesize that HIV-infected patients have higher rates of poor stroke outcomes compared to HIV-uninfected patients, and that this difference is, in part, attributable to the presence of concurrent central nervous system opportunistic infections.

Aim 2: To describe the clinical and radiologic characteristics of stroke in Uganda, with particular attention to differences by HIV serostatus. The investigators will describe the clinical presentation of stroke, including history and physical exam findings and presenting modified National Institutes of Health Stroke Scale (mNIHSS) score. The investigators will also compare radiologic characteristics, including location of the stroke and its classification as either ischemic or hemorrhagic. We hypothesize that: i) HIV-infected patients are predominantly younger at the time of presentation, ii) HIV infected-patients have more severe stroke presentations with higher mNIHHS scores, iii) HIV-infected patients are more likely to suffer from ischemic (versus hemorrhagic) stroke, and that iv) HIV-infected patients have a greater proportion of small vessel territory strokes due to the association with central nervous system infections and basal meningitis.

Aim 3: To identify the traditional and HIV-specific risk factors for poor outcome after stroke in Uganda. The investigators will fit regression models to identify predictors of poor outcomes as described in Aim 1, both in the total cohort, and restricted to the HIV-infected cohort. We hypothesize that age, presence of hypertension, dyslipidemia, smoking, and low Glasgow coma score are associated with PSO in Uganda and that HIV-specific predictors of poor outcome are low mid-upper arm circumference (MUAC), low CD4 cell count, high HIV viral load, and report of recent constitutional symptoms.

Study Design

Study Type:
Observational
Actual Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Impact of HIV-infection on Clinical Characteristics and Outcomes on Stroke in Uganda
Actual Study Start Date :
Feb 1, 2017
Actual Primary Completion Date :
Dec 1, 2020
Actual Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
HIV infected with stroke

No intervention will be administered

Other: Observational study
No intervention

HIV uninfected with stroke

No intervention will be administered

Other: Observational study
No intervention

Outcome Measures

Primary Outcome Measures

  1. Poor stroke outcome [30 days follow-up]

    modified Rankin Scale [mRS] > 2 or mortality

Secondary Outcome Measures

  1. Poor stroke outcome [1 year follow-up]

    modified Rankin Scale [mRS] > 2 or mortality

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥ 18 years old

  • In clinical care at the Mbarara Regional Referral, Mulago National Referral, or Nsambya Hospitals

  • Hospital presentation with features of new sudden-onset signs of focal or global disturbance of cerebral function lasting >24 hours (unless interrupted by surgery or death)

  • Stroke as presumed etiology of presentation

  • CT confirmation of stroke

Exclusion Criteria:
  • Presumed non-vascular etiology of neurodeficit (ie, trauma, tumor, brain abscess)

  • Pregnant, as defined by a positive urine beta-hCG

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mbarara Regional Referral Hospital Mbarara Uganda 00256

Sponsors and Collaborators

  • Mbarara University of Science and Technology
  • Massachusetts General Hospital

Investigators

  • Study Chair: Mark Siedner, MD, Massachusetts General Hospital
  • Principal Investigator: Amir Abdallah, MD, Mbarara University of Science and Technology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mbarara University of Science and Technology
ClinicalTrials.gov Identifier:
NCT03072212
Other Study ID Numbers:
  • 01/31-17
First Posted:
Mar 7, 2017
Last Update Posted:
Apr 5, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mbarara University of Science and Technology
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 5, 2022